Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Venactone, Soldactone
Synonyms :
Canrenoic acid
Class :
Aldosterone antagonist
Brand Name :
Venactone, Soldactone
Synonyms :
Canrenoic acid
Class :
Aldosterone antagonist
Dosage Forms & Strengths
Solution
200 mg
Not determined
None
may increase the hyperkalemic effect of potassium salts
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may enhance the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
antihypertensive actions of potassium-sparing diuretics can be reduced with combined NSAIDs
antihypertensive actions of potassium-sparing diuretics can be reduced with combined NSAIDs
antihypertensive actions of potassium-sparing diuretics can be reduced with combined NSAIDs
antihypertensive actions of potassium-sparing diuretics can be reduced with combined NSAIDs
antihypertensive actions of potassium-sparing diuretics can be reduced with combined NSAIDs
canrenoic acid may increase the excretion rate of almasilate, potentially lowering serum levels and reducing efficacy
may diminish the therapeutic effect of aldosterone antagonist
may increase the hyperkalemic effect of diuretics
may increase the hyperkalemic effect of angiotensin receptor II blockers
may increase the toxic effect of angiotensin receptor II blockers
may decrease the anti-hypertensive effect of nonsteroidal anti-inflammatory agents
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
drospirenone/ethinyl estradiol/levomefolateÂ
may increase the hyperkalemic effect of Drospirenone-Containing Products
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
Angiotensin II Receptor Blockers: they may increase the hyperkalemic effect of potassium-sparing diuretics
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
may have an increased hyperkalemic effect when combined with potassium-sparing diuretics
the risk of hyperkalemic activity may be increased
the risk of dehydration can be increased
Action and Spectrum:
Canrenoic acid is prodrug metabolized to aldosterone antagonist canrenone.
Aldosterone causes sodium absorption and potassium excretion by principal cells. Alpha intercalated cells in late distal tubule and collect duct exchange hydrogen and potassium ions.
Black box warning:
None
Contraindications/caution:
None
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
Potassium canrenoate blocks mineralocorticoid receptor.
Mineralocorticoid receptor responds to aldosterone, which regulates gene transcription. Crystal structure of its ligand-binding domain has been recently established.
Pharmacodynamics:
Aldosterone receptor antagonists inhibit aldosterone, which reduces sodium reabsorption, promotes water loss, lowers blood pressure, and decreases heart fluid.
Administration:
It is administered intravenously.
Patient information leaflet:
Generic Name: Canrenoic acid
Why do we use Canrenoic acid?
Canrenoic acid is indicated in patients with heart failure and myocardial infarction.
It is used in treatment of hyperaldosteronism and other disorders related to aberrant aldosterone levels.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
